Pertussis was a major childhood disease in parts of West Germany in 1990. Before a prospective household contact trial into the efficacy of an acellular pertussis vaccine was undertaken, the epidemiology of the disease was studied in one area. This study showed that pertussis had an annual incidence of 4%-6% in the first 6 years of life. During the trial, a total of 1223 pertussis cases were diagnosed by laboratory methods. Isolation rates of Bordetella organisms varied by the pediatrician who did the nasopharyngeal swab and decreased with time required for swab transport. Analysis of the serologic results showed that if IgG and IgA anti-pertactin antibodies had been considered, overall sensitivity would have been only marginally increased. Several pertussis patients had antibodies to parapertussis antigens, indicating a lack of complete cross-protection. The serologic response in secondary household contacts differed by vaccination status. However, this difference was unlikely to have influenced the point estimate of efficacy of the acellular vaccine.
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During the last decade, various phase III trials into the efficacy of acellular pertussis vaccines were planned in several countries. All areas or countries where trials were planned had to meet several prerequisites: These included sufficient pertussis cases and willingness of parents and guardians of children and ofpediatricians to participate in a trial. In addition, there was need for a common definition of the disease. Although various definitions of pertussis were tested, the basic case definition used in all trials was developed by a W orId Health Organization expert committee in 1991. This definition required 21 days of spasmodic cough in conjunction with a laboratory confirmation of recent contact with Bordetella organisms [1] .
When a trial [2] was proposed as a prospective household contact study, epidemiologic data in the study areas had to be gathered, and the logistics for laboratory diagnostics had to be set up before the trial was started. We report the peculiar history of pertussis in Germany and the epidemiologic situation before the study. In addition, we report various aspects of the serodiagnosis of pertussis in vaccinated and unvaccinated children studied during the vaccine trial.
Materials and Methods
Epidemiology. Before the study, there were few data on pertussis incidence in the former West Germany; the overall incidence during the late 1970s was estimated to be > 100,000 cases a year [3] . More detailed information about disease incidence was collected in one study area (Krefeld). Since an exact epidemiologic survey was not feasible, four data collection methods were combined to estimate the crude incidence of pertussis in the Krefeld area: isolation rates of the bacteria, parent recall at school entry, history of pertussis in hospitalized children, and a telephone poll among pediatricians [4] . It was assumed that if all four approaches pointed to similar incidences, this would approximate the crude overall incidence of pertussis in the area.
Laboratory methods. B. pertussis were isolated from nasopharyngeal (NP) swabs containing calcium alginate [5] . For transport, Regan-Lowe (RL) [6] medium was used. The swabs were preincubated in the pediatricians' offices overnight at 37°C before being sent to the local laboratory. Charcoal agar, which is superior to Bordet-Gengou agar for the isolation of Bordetella organisms from clinical material [5] , was supplemented with horse blood, and normal NP flora was inhibited by cephalexin. RL medium, which was used when the swabs were transported, was also used as an enrichment medium.
For serologic diagnosis, an increase in levels of antibodies to pertussis toxin (PT) or to filamentous hemagglutinin (FHA) in paired sera was required. We used standardized ELISA procedures with protocols similar to those in trials in Sweden and Italy. IgG and IgA antibodies to PT, FHA, and pertactin were measured [7, 8] , expressed in ELISA units per milliliter. An internal reference was used for constructing the reference line, whereas Food and Drug Administration -Center for Biologics Evaluation and Control reference sera 3 and 4 served as controls. The minimal level of detection was 1.9-3.0 U/mL and was arbitrarily set as 2.0 U/mL for all methods.
Recent contact with Bordetella pertussis antigens was assumed when there was an IgG or IgA conversion to~8 U/mL of PT, FHA, or both or when IgG or IgA antibodies to PT or FHA increased~100% to~8 U/mL. IgG and IgA antibodies to pertactin were not used for this definition. All acute sera were analyzed immediately after they reached the laboratory. An aliquot of these sera was analyzed a second time together with the convalescent sample. Correlation coefficients between the first and second analyses were 0.96 and 0.89 for IgG and IgA anti-PT, respectively; 0.93 and 0.96 for IgG and IgA anti-FHA, respectively; and 0.98 and 0.96 for IgG and IgA anti-pertactin, respectively. Intraassay serol-ogy varied from 3.0% (anti-FHA IgA) to 14.0% (anti-PT IgA). It did not differ significantly between the beginning and the end of the trial and was similar for reference sera with low-and highantibody contents. Both inter-and intraassay variations were similar to those reported by other laboratories [9] .
Results
History ofpertussis in Germany. Vaccination with whole cell pertussis vaccine was introduced in West Germany in the late 1950s but was never mandatory, whereas vaccination with diphtheria-tetanus toxoid-pertussis (DTP) vaccine became obligatory in 1964 in the former East Germany [10] . In 1963, notification for pertussis cases was discontinued in West Germany but remained notifiable in East Germany. The disease itself seemed to be under control at that time with a vaccination coverage of~80%. After Strom [11] questioned the need for pertussis vaccination in 1960, there was intensive discussion about possible severe side effects of DTP in West Germany in the late 1960s and early 1970s. This movement was further stimulated by data from Ehrengut [12] , who estimated the frequency of severe neurologic damage after DTP vaccination at 1 in 20,000. As a consequence, the number of pediatricians who used DTP vaccine decreased sharply, and the disease was observed more frequently shortly thereafter.
In 1974, the public pressed the Standige Impfkommission beim Bundesgesundheitsamt, an expert advisory body for vaccinations, to discontinue recommending DTP vaccination. DTP vaccination was then recommended only for infants at high risk and for those living under poor social conditions [13] . After that, the acceptance of pertussis vaccination decreased even more. In Germany, vaccinations are recommended by state (Lander) authorities, which mostly follow federal recommendations. The final decision is made by the individual pediatrician, who can be held responsible for all severe side effects of vaccines not recommended by state authorities. This explains, in part, why areas of relatively high coverage (50%-65%) were in close vicinity to areas where there was virtually no vaccine use.
In 1989, 60 pediatricians were surveyed by their colleagues about their attitude towards pertussis vaccination. Only 13 reported they vaccinated groups at risk against whooping cough; 16 said they would administer DTP vaccine to those at risk but had not actively done so. Thirty-one were totally opposed to the use of pertussis vaccine; however, the majority (66%) stated they would be willing to participate in a field trial of acellular pertussis vaccines.
We gathered data about vaccination coverage in the study areas and assumed that the incidence of the disease would be high in areas with low vaccine coverage. Vaccine uptake data were available from various areas (figure 1). All available data pointed to very low vaccine coverage [14 -17] in the study centers.
Epidemiologic data. Between 1987 and 1990, 4597 NP swabs were received from pediatricians, which yielded 844 B. pertussis and Bordetella parapertussis isolates. We assumed a 1:1 ratio between pertussis cases and NP swabs and a culture sensitivity of~50% [18] . From these data, we estimated a 5.2% annual incidence for children <6 years old.
The records of all children born either in 1982 or 1985 and hospitalized during 1988 in a central hospital were monitored. A total of 28% of 6-year-olds and 15% of 3-year-olds had a history of pertussis. This pointed to a mean annual incidence of 4.8%.
Vaccination records and parental information about infectious diseases during the first 6 years of life were collected at the school entrance examination, which is mandatory for all children. Data for incidence of whooping cough and pertussis vaccination were monitored for 2418 children born in 1976 and 1983. The mean pertussis incidence for both cohorts showed no significant difference between an urban (Krefeld) (5.5%) and a rural (Viersen) (6.4%) area. In the urban area, the pertussis incidence was similar in the 1976 and the 1983 cohort (5.1 % and 5.9%, respectively) as was the vaccine uptake (13.6% and 11.9%). The incidence in the rural area decreased from 7.2% in the 1976 cohort to 5.6% in the 1983 cohort, while vaccination coverage increased from 2.7% to 17.0%. Finally, 60 pediatricians were asked in 1989 about the frequency of pertussis. They estimated a mean annual incidence of 4.7% for the first 6 years of life. These results are shown as an overall estimate of incidence for the former West Germany in figure 2 and are compared with the estimated incidence of pertussis in the former East Germany, the United Kingdom, and the United States [4, 10, 19, 20] .
Laboratory results. Even before the study, differences in isolation rates of Bordetella organisms were observed among pediatricians who followed the same basic diagnostic procedures. Thus, we compared different practices and assumed that Year the number of infants entering the practice each year would be an adequate denominator for its size. As shown in table I, the isolation rates of B. pertussis per infant and year differed by almost one order of magnitude and did not seem to depend on the size of the physician's practice. As a consequence, all participating pediatricians were trained in the swabbing technique.
The transport time of swabs between the pediatricians' offices and the laboratory was known to influence the recovery of bacteria from swabs. The isolation rate of B. pertussis and B. parapertussis, which were artificially adsorbed in various dilutions onto calcium alginate swabs, was not significantly different between the study laboratories (n = 5), but it was influenced by the transportation time. Isolation rates differed by two orders of magnitude when the transportation time was increased from 48 to 120 h. As a consequence, it was decided to use local laboratories (Flensburg, Gottingen, Krefeld, Mainz, Trier) for bacteriology and a central laboratory (Krefeld) for serology.
During the trial, 1223 pertussis cases were diagnosed by laboratory methods. The distribution of these cases in the different study centers is shown in table 2. Apart from the center at Trier, the relation of suspected cases to proven cases was similar, which enabled combined analysis of the results from the different study centers.
Pertussis was isolated from 531 swabs (12.2%) from 4339 children studied. Of the 531, 518 swabs (97.6%) yielded B. pertussis, 11 (2.1 %) had B. parapertussis, and there were 2 coisolations of both organisms. The rate of B. parapertussis isolation ranged from 5.5% (Flensburg) to 1.3% (Krefeld). Figure 3 shows the numbers of Bordetella organisms isolated at two centers (Krefeld and Offenburg) during the trial. This study was influenced by an outbreak of pertussis that lasted from late 1993 to mid-1994.
B. pertussis was isolated in 37 children for whom we also received paired blood samples obtained in the required time interval. Of these, 3 showed no seroconversion, whereas 1 child had high antibody levels in acute serum, which did not increase sufficiently to comply with the definition of the disease. Tn addition, 655 culture-negative cases were diagnosed by a titer increase of specific antibodies to PT, FHA, or both. Table 3 shows that antibodies were found in similar frequencies in the culture-positive and culture-negative cohorts. About 36% of the children seroconverted, whereas 64% had antibodies to B. pertussis antigens, mostly in low concentrations, in their acute serum samples.
As antibodies to pertactin were not used in diagnosis, our data could also be used to analyze the role of IgG and IgA anti-pertactin antibodies to define recent contacts. Only 16 children, 14 of whom had detectable antibodies to PT, FHA, or (27) 131 (20) NOTE. PT, pertussis toxin; FHA, filamentous hemagglutinin.
both, seroconverted to pertactin without fulfilling other criteria for positive serology. These acute sera contained high levels of antibodies to PT or FHA, but the increase was not sufficient to comply with the definition. Two children seroconverted to pertactin without having antibodies to PT or to FHA. Thus, our data indicate that including anti-pertactin in the definition of recent contact with B. pertussis would have increased the number of positive cases by only 2%. Thirty-eight children had high levels of anti-FHA IgG (> 100 U/mL) in their acute serum sample and subsequently had PT seroconversion. The mean age of this subgroup (5.74 years) was significantly different (P < .00 1) from that of the culturenegative, serologically positive group as a whole (3.93 years; n = 655). A cross-check was done of the children (n = 24) who had high levels of anti-PT IgG (> 100 U/mL) in their acute sera and who later had FHA seroconversion. The mean age of this cohort (3.64 years) did not differ significantly from the overall mean age. Thus, we believe that high titers of FHA in the acute serum sample may reflect prior contact with B. parapertussis antigens, the percentage of which (5.5%) corresponded to the B. parapertussis isolation rate in the study areas (see above) [4, 20] .
We also compared the rate of seroconversion and of titer increase in the group of secondary contacts by their vaccination status. We compared all secondary contacts with typical index cases, who coughed ?:=7 days, regardless of their laboratory status. Whereas 12% of the unvaccinated symptomatic secondary contacts had no detectable antibody responses, none of the acellular vaccine group and only 2 patients in the whole cell vaccine group had no antibodies in their acute serum samples (table 4) . Detectable levels of IgG antibodies without a significant titer increase in the convalescent sample were found in 14% of the unvaccinated group, 27% of the group given acellu- lar vaccine, and 60% of the whole cell vaccine group. We think this difference was unlikely to have influenced the point estimate of the acellular vaccine's efficacy, as 26% of the unvaccinated group and 27% of the acellular vaccine group showed no titer increase. Differences among these groups were also observed in respect to the antibodies produced (table 4) : Increases in antibodies to PT, FHA, or both were found in 51% of the unvaccinated group, whereas anti-pertactin (alone or together with anti-P'T or anti-FHA) increased in 23% of these patients. In contrast, only 6% of the acellular vaccine group and none of the whole cell vaccine group had increases in anti-P'T or anti-FHA, whereas 67% and 34% of these groups, respectively, displayed increased levels of anti-pertactin antibodies (alone or together with anti-PT or anti-FHA).
In regard to the production of IgA antibodies (table 4), the differences between the 3 groups were less pronounced. Of all patients, 64%-80% did not produce IgA antibodies at all. The conversion rates of anti-PT and anti-FHA IgA were similar in all 3 groups. The acellular vaccine group had a higher percentage of children with detectable IgA antibodies in the acute sera, which did not significantly increase in the convalescent sample.
Discussion
A comparison of the estimated rates of pertussis in West Germany with data from Italy [21] and the United Kingdom [20] shows similar disease incidence, which seemed to depend mainly on the degree of vaccine uptake [20] .
The laboratory diagnosis of pertussis depends both on the direct isolation of the bacteria and on a detectable increase in antibody levels [18] . Before initiating a large efficacy trial, we tried to define the parameters that could influence the sensitivity of isolation of Bordetella organisms from NP swabs. We confirmed the previous observation [5] that the isolation rates relied heavily on the transport time. This prompted us to decentralize the bacteriologic laboratories. It had also been long suspected that variations in the swab procedure would influence the isolation rate of Bordetella organisms. Our data that preceded the trial (table 1) provide evidence that isolation rates among pediatricians differ by almost one order of magnitude. As a consequence, all participating pediatricians were trained individually; however, differences in Bordetella isolation rates between the study centers remained impressive (table 2) . Concomitant infection with B. pertussis and B. parapertussis, which is still not completely understood, was also found.
When the overall isolation rate was compared with another German trial, the proportion of swabs positive for B. pertussis was very similar [22] . Because erythromycin is widely used in Germany, we expected the overall isolation rates to be lower than found in trials in Sweden and Italy [23, 24] , where the use of erythromycin was restricted. Thus, the serologic diagnosis of pertussis was even more important. The antibody profiles in children were similar among culture-positive and culture-negative cases, which corresponds to previous data from Sweden [8] .
Some serologic data deserve special attention. As suggested by others [25] , the measurement of anti-pertactin IgG and IgA increased the overall positivity by only 2% and thus does not seem to be a valuable tool for the serologic diagnosis of pertussis.
Thirty-eight children had high anti-FHA titers in their acute sera and converted to PT later. Because of the significantly higher mean age of this group, we assume that these children had prior contact with B. parapertussis antigens and were infected with B. pertussis at the time of the study. This assumption, earlier addressed by Lautrop and others [26] [27] [28] , was recently documented by Taranger et al. [28] and is thought to be due to the lack of complete cross-immunity between pertussis and parapertussis.
As had been expected, differences in antibody profiles of isotype IgG were observed between nonvaccinated children and recipients of acellular and whole cell vaccines. Differences in IgA antibody profiles were marginal. Although an influence on the estimate of the efficacy of the whole cell vaccine could not be excluded, these differences were not likely to have influenced the point estimate of the efficacy of the acellular vaccine, as 26% of the unvaccinated group and 27% of the acellular vaccine group had no significant titer increase.
